Bio

Dr. Tehrani is a board-certified, fellowship-trained interventional cardiologist with Stanford Health Care Tri-Valley in the East Bay.

He is focused on building long-term relationships with his patients and their families, while sharing his evidence-based expertise in the noninvasive and minimally invasive management of cardiovascular disease. He takes pride in forming care plans based on mutual decision-making.

Dr. Tehrani’s research interests include cutting-edge technology and advancements in medical management of cardiovascular disease. His clinical research studies and funded clinical research trials have focused on cardiovascular biomarkers, coronary physiology, cardiac hemodynamics, cardio-oncology, and procedural closure devices. His research background has been instrumental in helping him provide individualized, evidence-based care plans for conditions ranging from advanced heart failure to complex coronary disease.

Dr. Tehrani has an extensive clinical research background, with over 40 peer-reviewed publications in top cardiology journals. He has done over 30 presentations at conferences, including the American Heart Association (AHA) and American College of Cardiology (ACC) national meetings.

Dr. Tehrani is a member the American College of Cardiology, the American College of Physicians, the American Heart Association, the Heart Failure Society of America, and the International Society of Heart and Lung Transplantation.

Clinical Focus

  • Cardiovascular Disease

Professional Education

  • Board Certification: Certification Board of Nuclear Cardiology, Nuclear Cardiology (2021)
  • Board Certification: American Board of Internal Medicine, Internal Medicine (2019)
  • Board Certification: American Board of Internal Medicine, Interventional Cardiology (2023)
  • Fellowship: UCLA Medicine Education Office (2023) CA
  • Board Certification: American Board of Internal Medicine, Cardiovascular Disease (2022)
  • Fellowship: UCLA Medicine Education Office (2022) CA
  • Residency: University of Chicago Hospitals Internal Medicine Residency (2019) IL
  • Medical Education: University of California Irvine (2015) CA

Contact

  • Clinical (Primary)  SHC Cardiovascular Health 5565 W Las Positas Blvd Ste 150 Pleasanton, CA 94588 (925) 278-7015 (fax)

Additional Clinical Info

All Publications

  • Suture-Mediated Vascular Closure forIntermediate-Bore FemoralVenousAccess. JACC. Clinical electrophysiology Parikh, R. V., Tehrani, D. M., Seto, A. H. 2024; 10 (8): 1837-1839

    View details for DOI 10.1016/j.jacep.2024.05.040

    View details for PubMedID 39197969

  • Comparison of Cardiac Allograft Vasculopathy Incidence Between Simultaneous Multi-Organ and Isolated Heart Transplant Recipients in the United States. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation Shahandeh, N., Kim, J. S., Klomhaus, A. M., Tehrani, D., Hsu, J. J., Nsair, A., Khush, K. K., Fearon, W. F., Parikh, R. V. 2024

    Abstract

    Prior studies have shown reduced development of cardiac allograft vasculopathy (CAV) in multi-organ transplant recipients. The aim of this study was to compare the incidence of CAV between isolated heart transplants and simultaneous multi-organ heart transplants in the contemporary era.We utilized the Scientific Registry of Transplant Recipients to perform a retrospective analysis of first-time adult heart transplant recipients between January 1, 2010 and December 31, 2019 in the United States. The primary endpoint was the development of angiographic CAV within 5 years of follow-up.Among 20,591 patients included in the analysis, 1,279 (6%) underwent multi-organ heart transplantation (70% heart-kidney, 16% heart-liver, 13% heart-lung, and 1% triple-organ) and 19,312 (94%) were isolated heart transplant recipients. The average age was 53 years and 74% were male. There were no significant between-group differences in cold ischemic time between the groups. The incidence of acute rejection during the first year after transplant was significantly lower in the multi-organ group (18% vs. 33%, p<0.01). The 5-year incidence of CAV was 33% in the isolated heart group and 27% in the multi-organ group (p<0.0001); differences in CAV incidence were seen as early as 1 year after transplant and persisted over time. In multivariable analysis, multi-organ heart transplant recipients had a significantly lower likelihood of CAV at 5 years (hazard ratio=0.76, 95% confidence interval: 0.66-0.88, p<0.01).Simultaneous multi-organ heart transplantation is associated with significantly lower long-term risk of angiographic CAV compared with isolated heart transplantation in the contemporary era.

    View details for DOI 10.1016/j.healun.2024.06.014

    View details for PubMedID 38950666

  • How much does CMD cost before it is diagnosed? Cardiovascular revascularization medicine : including molecular interventions Seto, A. H., Tehrani, D. M. 2024

    View details for DOI 10.1016/j.carrev.2024.04.016

    View details for PubMedID 38641439

  • Early Trends in Cardiac Allograft Vasculopathy After Implementation of the 2018 Donor Heart Allocation Policy in the United States: Short Title: CAV Trend After Allocation Policy Change. American heart journal Tehrani, D. M., Kim, J. S., Hsu, J. J., Nsair, A., Khush, K. K., Fearon, W. F., Parikh, R. V. 2022

    Abstract

    STUDY OBJECTIVE: To evaluate the impact of the new donor heart allocation system implemented in the United States in October 2018 on development of early cardiac allograft vasculopathy (CAV).DESIGN: Retrospective cohort study.PARTICIPANTS: Adult (≥ 18 years) heart transplant recipients registered in the United Network for Organ Sharing database between October 18, 2015 - October 17, 2018 (old system) and October 18, 2018 - May 31, 2020 (new system).MAIN OUTCOME MEASURE: Incidence of angiographic CAV at 1 year (accelerated CAV) in the overall transplant population and among the highest acuity subgroup-Status 1A (old) and Status 1 or 2 (new). We included recipient and donor demographic, cardiovascular, and transplant factors in multivariable logistic regression models to identify predictors of accelerated CAV.RESULTS: Of 10,375 transplant recipients, 6,660 (64%) and 3,715 (36%) were listed in the old and new allocation cohorts, respectively. The incidence of accelerated CAV was 521 (8%) in the old period compared with 272 (7%) in the new period (p = 0.36). Similar incidence rates were observed in the highest acuity subgroup-363 (8%) compared with 143 (7%), respectively (p = 0.13). In adjusted analyses of the high-acuity cohort, the new allocation system was not associated with a higher likelihood of accelerated CAV (odds ratio = 0.87, 95% confidence interval: 0.70-1.08, p = 0.20).CONCLUSIONS: The new donor heart allocation system is not associated with development of accelerated angiographic CAV at 1 year, including among recipients requiring the most urgent transplants.

    View details for DOI 10.1016/j.ahj.2022.08.002

    View details for PubMedID 35970399